In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

As Amgen waits for an FDA decision on a second indication for its B cell-depleting therapy Uplizna, it has new data suggesting a third may be coming down the pipe. New data from the phase 3 MINT ...

It has some rivals in its push to the IgG4-RD market, notably Amgen which reported positive topline results from a phase 3 trial of its CD19-directed antibody Uplizna (inebilizumab), acquired as ...

Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen AMGN revealed 19 unusual trades. Delving into the details, we found 26% of traders were ...

The case had been filed last year by Amgen after the state Prescription Drug Affordability Board determined that its big-selling medication called Enbrel is unaffordable and began a process to ...

Based on Wall Street analyst estimates for 2025 EPS, Amgen trades at 15 times its projected earnings, while Merck sits at a forward P/E of 10. By this measure, Merck is the cheaper stock and a ...

The Phase III MITIGATE trial demonstrated that Uplizna (inebilizumab) significantly reduces the risk of flares, lowers glucocorticoid dependence, and increases rates of treatment- and ...

Based on additional results from the Phase III PSMAfore clinical trial, the therapy is now approved for use prior to chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer. The ...

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for Immutep Global Phase III with efti will enrol approximately 756 patients at more than ...